Prescription drug · ANDA
Verapamil hydrochloride NDC 68382-562
Verapamil hydrochloride 180 mg/1 · Tablet · Oral · Zydus Pharmaceuticals (USA) Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68382-562-01 | 68382056201 | 100 TABLET in 1 BOTTLE (68382-562-01)Marketed from May 21, 2026 | |
| 68382-562-05 | 68382056205 | 500 TABLET in 1 BOTTLE (68382-562-05)Marketed from May 21, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Verapamil hydrochloride
- Generic name (nonproprietary)
- verapamil hydrochloride
- Active ingredients
- Verapamil hydrochloride — 180 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 219252
- Marketing start
- Listing expires
- Other FDA classes
- Calcium Channel Antagonists (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
- Identifiers
- Product ID 68382-562_ffca6bb5-e52a-426d-8f93-5e0e8da34eedSPL ID ffca6bb5-e52a-426d-8f93-5e0e8da34eedSPL set ID e19ab8d8-dae5-489d-9805-7e7407bea06dRxCUI 897640, 897649, 897659UNII V3888OEY5R
- Pharmacologic class
- Calcium Channel Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N468382056201followed by a unit qualifier and the quantityPackage 68382-0562-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one d…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 219252
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Verapamil hydrochloride | Verapamil hydrochloride 120 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1953 |
| Verapamil hydrochloride | Verapamil hydrochloride 180 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1954 |
| Verapamil hydrochloride | Verapamil hydrochloride 240 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1955 |
| Verapamil hydrochloride | Verapamil hydrochloride 120 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 68382-561 |
| Verapamil hydrochloride | Verapamil hydrochloride 240 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 68382-563 |